# Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

> **NCT05841472** · PHASE2 · RECRUITING · sponsor: **CrystalGenomics, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Non Squamous Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin

## Key facts

- **NCT ID:** NCT05841472
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-23
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841472, "Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05841472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*